Nanjing Vazyme Biotech Co Ltd - Asset Resilience Ratio
Nanjing Vazyme Biotech Co Ltd (688105) has an Asset Resilience Ratio of 38.60% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Nanjing Vazyme Biotech Co Ltd total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Nanjing Vazyme Biotech Co Ltd's Asset Resilience Ratio has changed over time. See 688105 net asset value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Nanjing Vazyme Biotech Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Nanjing Vazyme Biotech Co Ltd worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.93 Billion | 38.6% |
| Total Liquid Assets | CN¥1.93 Billion | 38.60% |
Asset Resilience Insights
- Very High Liquidity: Nanjing Vazyme Biotech Co Ltd maintains exceptional liquid asset reserves at 38.60% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Nanjing Vazyme Biotech Co Ltd Industry Peers by Asset Resilience Ratio
Compare Nanjing Vazyme Biotech Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.10% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 30.29% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 4.52% |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180 |
Biotechnology | 4.28% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 83.49% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 41.74% |
Annual Asset Resilience Ratio for Nanjing Vazyme Biotech Co Ltd (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Nanjing Vazyme Biotech Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 44.01% | CN¥2.22 Billion ≈ $325.15 Million |
CN¥5.05 Billion ≈ $738.78 Million |
+17.66pp |
| 2023-12-31 | 26.35% | CN¥1.51 Billion ≈ $221.55 Million |
CN¥5.75 Billion ≈ $840.85 Million |
-2.28pp |
| 2022-12-31 | 28.63% | CN¥1.72 Billion ≈ $251.58 Million |
CN¥6.01 Billion ≈ $878.75 Million |
-14.26pp |
| 2021-12-31 | 42.89% | CN¥1.98 Billion ≈ $289.13 Million |
CN¥4.61 Billion ≈ $674.17 Million |
-6.48pp |
| 2020-12-31 | 49.37% | CN¥795.65 Million ≈ $116.43 Million |
CN¥1.61 Billion ≈ $235.83 Million |
+49.35pp |
| 2019-12-31 | 0.02% | CN¥50.00K ≈ $7.32K |
CN¥324.33 Million ≈ $47.46 Million |
-- |
About Nanjing Vazyme Biotech Co Ltd
Nanjing Vazyme Biotech Co., Ltd offers technology solutions for life science, biomedicine, and in vitro diagnostics. The company offers nucleic acid extraction reagents, including DNA extraction, RNA extraction, microbiome nucleic acid extraction, sample treatment, and high-throughput automated extraction; molecular biology reagents comprising PCR, cloning/mutagenesis, reverse transcription, real… Read more